The Rise of Outsourcing in the Pharmaceutical Industry

As drug development has become more complex and costly over the past few decades, pharmaceutical companies have increasingly turned to outsourcing non-core functions to specialty contract research organizations (CROs). CROs first emerged in the 1970s to help pharmaceutical firms with individual projects like clinical trials management and regulatory support. However, their role has expanded dramatically as biopharma looks to contain escalating research and development (R&D) costs. The U.S. CROs market accounts for the largest share due to presence of top CROs and supporting regulations.

Key Services Offered by Leading U.S. CROs

Major U.S.-based CROs offer a diverse range of drug development services across the entire life cycle. Preclinical services include toxicology studies, lead optimization, drug metabolism/pharmacokinetics testing, bioanalytical analysis, and more. In clinical development, U.S. Contract Research Organizations responsibilities cover Phase I to Phase IV trials including protocol design, monitoring, data management, biostatistical analysis and medical writing. Many CROs also provide post-approval services like pharmacovigilance monitoring, Phase IV outcomes research trials, and epidemiological research. Beyond R&D, key outsourced areas include regulatory consulting, medical affairs, commercialization capabilities, and digital technologies for remote trials and telemedicine. Top CROs have also expanded geographically to support global clinical trials. Through innovative service bundles and global infrastructure, CROs aim to provide end-to-end solutions for outsourced clinical and research needs.

Get More Insights on U.S. Contract Research Organizations